Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified.
This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention.
The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations.
Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted.
Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.
Mots-clés Pascal : Programme sanitaire, Prévention, SIDA, Virose, Infection, Ciblage, Risque élevé, Analyse coût efficacité, Economie santé, Homme, Evaluation, Immunopathologie, Immunodéficit, Population cible
Mots-clés Pascal anglais : Sanitary program, Prevention, AIDS, Viral disease, Infection, Targeting, High risk, Cost efficiency analysis, Health economy, Human, Evaluation, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0152659
Code Inist : 002B30A01C. Création : 21/05/1997.